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Several published studies identified associations of a number of polymorphisms with a variety of survival outcomes in colorectal
cancer. In this study, we aimed to explore 102 previously reported common genetic polymorphisms and their associations with
overall survival (OS) anddisease-free survival (DFS) in a colorectal cancer patient cohort fromNewfoundland (𝑛 = 505). Genotypes
were obtained using a genomewide SNP genotyping platform. For each polymorphism, the best possible genetic model was
estimated for both overall survival and disease-free survival using a previously published approach.These SNPs were then analyzed
under their genetic models by Cox regression method. Correction for multiple comparisons was performed by the False Discovery
Rate (FDR) method. Univariate analysis results showed that RRM1-rs12806698, IFNGR1-rs1327474, DDX20-rs197412, and PTGS2-
rs5275 polymorphisms were nominally associated with OS or DFS (𝑝 < 0.01). In stage-adjusted analysis, the nominal associations
of DDX20-rs197412, PTGS2-rs5275, and HSPA5-rs391957 with DFS were detected. However, after FDR correction none of these
polymorphisms remained significantly associated with the survival outcomes. We conclude that polymorphisms investigated in
this study are not associated with OS or DFS in our colorectal cancer patient cohort.
1. Background
Colorectal cancer is one of the most frequently diagnosed
malignancies. Advances in treatment and implementation
of screening programs decrease its incidence and mortality
rates; however, the current 5-year survival rate for colorectal
cancer is considered only “relatively good” (62–65%) inNorth
America [1, 2]. In other parts of the world, the survival rates
for this disease are more disappointing (30–54%) [3].
Variability between the initial prognostic estimations and
the actual outcomes observed in patients underlines the
need to improve the prognostic estimations. Additional and
possibly multiple prognostic predictors may help improve
the prediction models by helping better discriminating the
patients with different possible disease outcomes [4].
Polymorphic genetic variations, such as single nucleotide
polymorphisms (SNPs), exist in large numbers in the human
genome [5]. Genetic polymorphisms are candidate prog-
nostic markers because of their variability among different
individuals and their potential role as the biologicalmodifiers
of outcome risk. Similar to other cancer sites, in colorectal
cancer several polymorphisms have been identified as being
associated with a variety of survival outcomes.
The aim of this study was to investigate whether polymor-
phisms that were reported in the literature to be associated
with survival outcomes were associated with select survival
outcomes in our patient cohort. Specifically, we tested the
associations of 102 SNPs from 73 genes and genetic loci with
overall and disease-free survivals in a cohort of colorectal
cancer patients from Newfoundland (𝑛 = 505).
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 968743, 9 pages
http://dx.doi.org/10.1155/2015/968743
2 BioMed Research International
2. Methods
2.1. Ethic Statement. All patients or their family members
provided written consent to use of patient biospecimen and
access to medical information. This study was approved by
the Human Investigation Committee (HIC, recently named
asThe Health Research Ethics Authority (HREA)) of Memo-
rial University of Newfoundland. During this study, patient-
related data were kept anonymous to the researchers who
analyzed the data.
2.2. Patient Cohort. The patient cohort investigated in this
study is a subcohort of the patients recruited to the New-
foundland Colorectal Cancer Registry (NFCCR). NFCCR
was described in detail previously [6]. Briefly, in a five-
year period (1999–2003), patients diagnosed with colorectal
cancer in Newfoundland were contacted and 750 colorectal
cancer patients were recruited to NFCCR. Clinical and
prognostic data for patients were collected as described in
Negandhi et al. [7]. Microsatellite instability (MSI) status for
tumor samples was determined using molecular techniques
as described by Woods et al. [8]. The last date of follow-
up was April 2010. Among 750 patients, 505 Caucasian and
unrelated stage I–IV patients for whom the clinical, genetic,
and prognostic data were available and whose genotype data
passed the quality control measures and satisfied the inclu-
sion criteria were included in this study (see the following
paragraph).
Cohort characteristics are summarized in Table 1. The
majority of the patients were male (60.8%). Proportion of
patients with colon tumors (66%) and MSI-L/MSS tumors
(85.4%) were higher than the patients with rectal cancer and
MSI-H tumors. The median follow-up times for OS and DFS
were 6.36 years (range: 0.38–10.88) and 6 years (range: 0.22–
10.88), respectively. During the follow-up, a total of 170 deaths
(the number of events for OS analysis) and 200 recurrences,
metastases, or deaths (the number of events in the DFS
analysis) were observed in this cohort.
2.3. Genotyping Experiment, Quality Control Measures, and
Inclusion Criteria. The venous blood samples of patients
were collected at the time of recruitment and genomic
DNA samples were extracted. Genotyping experiments were
performed for 539 patients with available prognostic data
at a service provider (Centrillion Biosciences, USA) using
the IlluminaHumanOmni1-Quad SNP genotyping platform.
This cohort contains >1 million SNP markers. The following
quality control (QC)measureswere taken to exclude samples:
patientswith ambiguous gender information (based on theX-
chromosome genotype data compared to the self-identified
sex, 𝑛 = 1), first, second, and third degree relatives among the
patients based on the identity-by-state PHI-hat score (>0.125,
𝑛 = 21), patients with low heterozygosity rate determined
based on ±3 SD from the mean (𝑛 = 1), and non-Caucasian
patients based on the multidimensional scaling method and
principal component analysis (𝑛 = 11). Genotyping of no
sample was accidently duplicated. All patients had successful
Table 1: Clinicopathological, molecular, and treatment-related
characteristics of the patients included in this study.
Variables 𝑛 (%)
Sex
Female 198 (39.21)
Male 307 (60.79)
Age at diagnosis Median: 61.43 years(range: 20.7–75)
Histology
Nonmucinous 448 (88.71)
Mucinous 57 (11.29)
Location
Colon 334 (66.14)
Rectum 171 (33.86)
Stage
I 93 (18.42)
II 196 (38.81)
III 166 (32.87)
IV 50 (9.9)
Grade
Well/moderately differentiated 464 (91.88)
Poorly differentiated 37 (7.33)
Unknown 4 (0.79)
Vascular invasion
Absent 308 (60.99)
Present 159 (31.49)
Unknown 38 (7.52)
MSI status
MSI-L/MSS 431 (85.35)
MSI-H 53 (10.5)
Unknown 21 (4.16)
genotypes rates of >95%. As a result, 505 unrelated and
Caucasian colorectal cancer patients who met these QC
measures and inclusion criteria were included in this study
(Table 1).
2.4. Selected Genes and Polymorphisms. The dbCPCO data-
base [9] summarizes the findings of studies testing the
associations of genetic variations with clinical outcomes in
colorectal cancer. In brief, genes, polymorphisms, outcomes
investigated, patient characteristics, results of the statistical
tests for outcome measure(s) investigated, and other relevant
information are curated from eligible published reports and
are posted in the dbCPCO database. Eligibility criteria for the
publications include the following: being a research article
and including at least 20 patients in the analysis [9]. For
this study, we extracted the genetic polymorphisms that
were reported in at least one study/patient cohort to be
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SNPs in dbCPCO 
SNPs with available genotypes SNPs with no genotypes available 
Proxy SNPs with available genotypes Proxy SNPs with no available genotypes 
SNPs with proxy SNPs identified (r2 = 1) SNPs with no proxy SNPs (r2 < 1)
n = 149
n = 83 n = 66
n = 31
n = 25
n = 24 n = 7
MAF ≥ 5% = 102 SNPs (included) MAF < 5% = 5 SNPs (excluded)
Total SNPs: 83 + 24 = 107
Figure 1: MAF: minor allele frequency; SNP: single nucleotide polymorphism. A flowchart of the process in selecting the SNPs included in
this study.
associated with survival outcomes in multivariable analyses,
including overall, disease-free, cancer-specific, and disease-
specific survivals, time to recurrence/progression and risks
of recurrence or metastasis, and disease progression, as of
October 2013. Among these studies, we focused on only
the inherited genetic polymorphisms in the form of single
nucleotide polymorphisms (SNPs) and insertion/deletion
(indels) from the nuclear genes. Microsatellite markers and
haplotypes were excluded. In addition, SNPs from genes
that are genotyped and investigated by our group in either
published [7] (highly similar cohort with many patients
in common between the published and the present study
cohorts) or still ongoing studies (exactly the same patient
cohort; these studies with different research questions/candi-
date pathway approaches will be published later) were
excluded. One SNP with no rs number was also excluded
(RPH3AL -25C/A in 5󸀠-UTR). As a result, 149 polymor-
phisms from94 genes and other loci were initially selected for
this project (see Additional File-1 in SupplementaryMaterials
available online at http://dx.doi.org/10.1155/2015/968743).
2.5. Selected Genes, Polymorphisms, and Quality Control
Measures. We first searched the availability of genotype data
for the polymorphisms listed in Additional File-1 within the
genomewide genotype data using PLINK [10]. As a result,
genotype data for a total of 83 SNPs were available for our
patients. For the remaining SNPs (𝑛 = 66), we looked for the
SNPs that are highly correlated (𝑟2 = 1) using the Caucasian
(CEU) 1000 genomes Pilot 1 data in the SNAP database
(http://www.broadinstitute.org/mpg/snap/ldsearch.php) [11];
we reasoned that these “proxy” SNPs can be used to inves-
tigate the associations of these SNPs in our cohort as they
have identical genotype distributions (Additional File-1).This
search found an at least one proxy SNP for 31 of the 66
polymorphisms. For 24 of such proxy SNPs, there were
genotype data available for our patient cohort.Therefore, after
these steps, the genotype data of a total of 107 polymorphisms
were available in the patient cohort for investigation. The
minor allele frequencies (MAFs) of the SNPs in this patient
cohort ranged from 2 to 50%. Five SNPs with MAFs less
than 5% (rs11208727, rs5789, rs2272990, rs11986055, and
rs17226088) were excluded from the statistical analysis. As a
result, a total of 102 SNPs were included in the final statistical
analysis (Additional File-2). A flowchart of the SNP selection
approach is depicted in Figure 1.
Among these SNPs, two SNPswere reported as associated
with (at least) DFS, 64 SNPs were reported to be associated
with OS, and one SNP was reported to be associated with
both OS and DFS by others in the literature; all other
studies reported associations of the SNPs with other clinical
outcomes; a summary of the previous studies’ findings based
on the dbCPCO database can be found in Additional File-3.
2.6. Statistical Analyses. The outcome measures used in this
study were the overall survival (OS), defined as the date from
diagnosis till the date of death or the date of last contact (the
censored patients) and disease-free survival (DFS) defined as
the date fromdiagnosis till the date of diagnosis of recurrence
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ormetastasis or death, whichever occurred earlier, or the date
of last contact.
Initially, genotypes for each SNP were coded under
the codominant genetic model, in which the major allele
homozygotes, heterozygotes, and minor allele homozygotes
were categorized separately and coded as 0, 1, and 2, respec-
tively. Following a previously published approach [12], to
estimate the best possible genetic model that fits each poly-
morphism, Kaplan-Meier survival curves were constructed
using the codominant genetic model coding scheme for OS
and DFS separately. This step served as a prescreening of
SNPs for further statistical analyses and to estimate the best
genetic models for promising SNPs based on the pattern of
their Kaplan-Meier curves. During this step, SNPs for which
a genetic model could not be assigned (either because the
SNP genotypes did not show Kaplan-Meier curve separation
or the curves were close and/or crossing with each other
multiple times) were excluded from further analysis. Of note,
for these excluded polymorphisms the log-rank 𝑝 values
were supportive of their exclusion (>0.05), except in one
case (HS2ST1-rs9433110 in overall survival analysis) where
the log-rank 𝑝 value was <0.05 due to one patient with the
homozygous minor allele genotype who passed away soon
after the diagnosis, the curves of two other genotypes (AA
and Aa) did not separate; this SNP was therefore excluded
from further analysis. While there were other SNPs that had
log-rank 𝑝 values > 0.05 in this preselection analysis, they
were not excluded because of the separation of their curves
that helped us to estimate a suitable genetic model for their
analysis. Sometimes more than one genetic model seemed
to fit a SNP; in such cases, multiple models were assigned
to the SNPs. The SPSS outputs for Kaplan-Meier survival
curve analysis for OS and DFS as well as the estimated
geneticmodels are shown inAdditional File-4 andAdditional
File-5, respectively. When the number of patients in the
minor allele homozygote group was less than 10, recessive,
codominant, and additive models were not attempted; rather
the dominant genetic model was applied (if applicable). Once
the best genetic model(s) and the SNPs to be excluded
were determined, univariate Cox regression analysis was
performed for the final list of SNPs under the best genetic
models. In the case of SNPs with multiple candidate best
genetic models, the one with the smallest 𝑝 value derived
from the univariate Cox regression analysis was deemed to
be the best genetic model [13]. As per the request of an
anonymous reviewer, we also repeated the Cox regression
analyses for OS and DFS by adjusting for disease stage.
For SNPs, the reference group changed based on the
genetic model. For example, assuming AA, Aa, and aa donate
major allele homozygote, heterozygote, and minor allele
homozygote genotypes, the reference groups in recessive,
dominant, and codominant genetic models were AA+Aa,
AA, and AA, respectively.
To control for the false-positive rate, the False Discovery
Rate (FDR) method [14] was used; the cutoff of the FDR
adjusted 𝑝 value (𝑞 value) was 0.05. In this paper, polymor-
phisms that showed no statistically significant associations
after FDR adjustment (adjusted 𝑝 < 0.05) but had an
unadjusted 𝑝 < 0.01 are noted as nominally associated with
the outcomes.
We computed the power of the samples for genetic
association tests. Given a SNP in LD (𝐷󸀠 = 1) with a risk
allele frequency 0.3, we have 85% power to detect a significant
association at nominal significance 𝑝 value < 0.01 under a
dominant model with strong effect size of HR 1.8. To detect
an association with the same assumptions and FDR adjusted
𝑝 value < 0.05, the statistical power is reduced to 0.61. With a
moderate effect size of HR 1.5, the power to detect significant
association (FDR adjusted 𝑝 < 0.05) is very low.
Testing the proportionality assumption for Cox uni-
variate model was done based on the Schoenfeld residual
analysis using the “survival” package of R software [15]. The
cox.zph function calculates tests of the proportional hazards
assumption for each covariate. 𝑝 value greater than 0.05
means the proportional hazard assumption is valid. FDR
calculations were done using the R function p.adjust. Other
statistical analyses were performed by the SPSS (version 20,
IBM, USA) or R [15]. PLINK [10] was used for genotype
quality control and summary purposes.
2.7. PolyPhen-2 Analysis. A possible biological effect of
the nonsynonymous rs197412 polymorphism (Ile636Thr) on
DDX20 protein function was examined using the PolyPhen-2
tool [16].
3. Results and Discussion
In this study, we aimed to test the previously reported
associations of 102 genetic polymorphisms with survival
outcomes of colorectal cancer patients in a separate patient
cohort using overall and disease-free survivals as the outcome
measures.While the previous associationswere detectedwith
a variety of outcomes (including overall, progression-free,
recurrence-free, cancer-specific or disease-specific survivals,
time-to-recurrence and others), we reasoned that they may
be good candidates to systematically investigate in relation
to overall and disease-free survivals (two outcome measures
available for our patient cohort).
Genotype distributions of none of the 102 SNPs deviated
from the HWE (𝑝 values > 0.01). Genes, SNPs and their
polymorphic alleles, minor allele frequencies, the best genetic
models estimated for OS and DFS using the Kaplan-Meier
curves, and the best genetic models selected by the univariate
Cox regression method (in the case of SNPs with more than
one candidate genetic models) are shown in Additional File-
2.
For overall survival, at least one genetic model was
assigned to 65 of the 102 SNPs. For DFS, at least one genetic
model was estimated for 78 SNPs. These SNPs were further
investigated by statistical analyses (please see the following
paragraph). In both overall and disease-free survival analyses,
the recessive genetic model was the most frequently chosen
model while the additive model was the least chosen one.
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After the genetic model estimations, the univariate Cox
regression analysis was performed for the 65 SNPs in overall
survival and 78 SNPs in disease-free survival analysis under
the genetic models selected for them (Additional File-6 and
Additional File-7). Initially, our univariate analysis results
suggested nominal associations of four polymorphisms
(unadjusted 𝑝 < 0.01). Specifically, the minor allele con-
taining genotypes (genotypes AG and GG) for the IFNGR1-
rs1327474 polymorphism were associated with longer overall
survival times when compared to the major allele homozy-
gous genotype (AA) (Table 2). IFNGR1-rs1327474 polymor-
phism (NM 000416.2:c.-611G>A) is located near the 5󸀠-
end of the IFNGR1 gene [17] that codes for the ligand-
binding chain of the interferon gamma receptor 1 [18].
Previously association of this polymorphism with disease-
specific survival in colorectal cancer was reported [19]. In
addition, patients heterozygous for the RRM1-rs12806698
polymorphism had shorter overall survival times compared
to patients with the major allele homozygous (CC) genotype
(Table 2). According to the dbSNP database [17], the RRM1-
rs12806698 (NM 001033.3:c.-269C>A; also called -37A/C)
is a C/A substitution located in the 5󸀠-UTR of the RRM1
gene possibly affecting its expression [20]. A study previously
reported its association with time-to-progression in colorec-
tal cancer patients treated with gemcitabine [20].
In univariate disease-free survival analysis, nominal asso-
ciations (unadjusted 𝑝 values of <0.01) were detected for
three polymorphisms (Table 2). Similar to overall survival
results, patients with the AG and GG genotypes of the
IFNGR1-rs1327474 polymorphism had longer disease-free
survival times compared to patients with the AA geno-
type. Additionally, each C allele increased the disease-free
survival times in patients in the case of DDX20-rs197412
polymorphism. DDX20 (also called GEMIN3) is presumably
a RNA helicase involved in RNA processing [21]. DDX20-
rs197412 polymorphism results in a nonsynonymous amino
acid substitution (NP 009135.4:p.Ile636Thr T/C [17]). Based
on our analysis using the PolyPhen-2 tool [16], this non-
synonymous polymorphism is not predicted to affect the
protein function. Two other studies have so far investigated
this polymorphism in relation to survival outcomes in
colorectal cancer; while one study [22] found it associated
with recurrence-free survival, another study did not associate
it with overall and progression-free survivals [23]. Finally,
patients heterozygous for the PTGS2-rs5275 polymorphism
had worse disease-free survival times compared to patients
homozygous for the major allele (TT genotype). PTGS2 (also
known as Cox-2) encodes for cyclooxygenase enzyme that
functions in inflammation-related pathways [24]. The rs5275
polymorphism (NM 000963.2:c.*427T>C) is located in the
3󸀠-UTR of the PTGS2 gene [17]. This polymorphism was
previously predicted to be in a miRNA binding sequence;
however experimental analyses in lymphoblastoid cell lines
did not find an association of it with the PTGS2 expression
levels [25]. In a previous study, this polymorphismwas found
to be associated with progression-free and overall survivals in
colorectal cancer [26].
When the SNP genotypes were adjusted for disease
stage, no associations of the IFNGR1-rs1327474 and RRM1-
rs12806698withOSwere detected (𝑝 values> 0.01). However,
in DFS analysis, the nominal associations (𝑝 values < 0.01)
were obtained for theDDX20-rs197412 and the PTGS2-rs5275
genotypes (Table 2). Additionally, patients with the minor
allele containing genotypes (TC and TT) of the HSPA5-
rs391957 polymorphism had longer disease-free survivals
when compared to patients with themajor allele homozygous
genotype (CC) (Table 2). HSPA5 is a heat-shock protein
involved in protein folding activity within the endoplasmic
reticulum [27]. The C allele of this polymorphism was previ-
ously shown to create a transcription factor binding site and
to be associated with increased expression of theHSPA5 gene
[28]. In colorectal cancer, this polymorphism was previously
associated with time-to-recurrence in a patient cohort [29].
Kaplan-Meier curves for SNPs discussed are shown in
Figure 2. Of note, none of the five SNPs violated the Cox
proportional hazards assumption.
We then applied the FDRmethod to account for multiple
comparisons. After FDR correction, association of none
of the polymorphisms with outcomes remained significant.
Therefore, we can conclude that none of the investigated
polymorphisms showed statistically significant associations
with overall survival and disease-free survival in our patient
cohort. However, this may be in part because of the limited
sample size and the insufficient study power. Therefore, a
large cohort with a longer follow-up time may be needed for
further assessment of these genetic markers.
Limitations of this study should be mentioned as follows.
(i) While the polymorphisms were selected based on their
associations with a variety of survival outcomes in previous
studies on colorectal cancer, our study was limited with
testing their associations with overall survival and disease-
free survival only. In addition, the cohortsmight have differed
in terms of ethnicity or other population and disease related
characteristics, and the genetic models used during the
statistical analyses are likely to be different, too. Due to these
differences between our study and other studies, the results of
this study and other studies hence should be compared with
caution. (ii) Not all polymorphisms first identified through
the literature could be studied in this study due the lack of
their genetic data in our cohort. (iii) When compared to the
entire NFCCR patient cohort, the study cohort had a higher
proportion of stage I–III patients: this was due to the low
number of stage IV patients with DNA samples that was
available for the genotyping experiment.
4. Conclusions
In conclusion, there was no evidence of associations of the
102 polymorphisms investigated in this study with overall or
disease-free survivals in a colorectal cancer patient cohort
from Newfoundland.
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Figure 2:The 𝑝 values shown are obtained by the log-rank test. DFS: disease-free survival; OS: overall survival. Kaplan-Meier survival curves
for the polymorphisms with nominal associations (𝑝 value < 0.01).
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